hemodynamic conditions. A saccular aneurysm without collateral branch will thrombose quickly. If a collateral branch is present the flow is directed towards this branch leading to shrinkage of the aneurysm. Animal experiments show excellent results. Moreover, as demonstrated in animal and human studies this MFM* preserves the collateral branches allowing the possibility to cover any artery without compromising the flow (renal, digestive arteries, supra aortic vessels.) Results: 40 peripheral An. (iliac:23, femoral:1, popliteal:5, renal:8, mesenteric:1, carotid: 1, Subclavian : 1) were treated with the MFM* (male:31, mean age 62+/-8 y) (52 stents Ø 5 to 14 mm; length 40 to 120 mm) were implanted to treat these aneurysms, by femoral approach (39 cases), brachial approach (1 case), Technical success in all patients. No complications. All An. thrombosed with diameter reduction in some pts. The thrombosis could take several weeks depending on the importance of collateral branches. 6 month to 36 month follow up will be presented and we will discuss the time needed to achieve exclusion of the An. All the side branches remained patent. Conclusions: A new concept of stent, the MFM* (without any covering) is developed to treat An. It opens a new approach to treat peripheral An. avoiding most of the complications encountered with current endovascular techniques. The results obtained seem promising. A larger study is ongoing. The Ohio State Univeristy, Columbus, OH Background: Central sleep apnea (CSA), usually presenting as Hunter-CheyneStokes Breathing, occurs in approximately 35% of patients with heart failure. Current treatment options for CSA have been limited and focus on mask based therapies and therefore are highly dependent on tolerability and adherence. A novel therapy utilizing phrenic nerve stimulation was developed using the remed e System, a transvenous, fully implantable system that is intended to restore a normal breathing pattern throughout the night. This is the first presentation of the study cohort with reduced ejection fraction (EF) to evaluate of the remed eÒ System through 3 and 6 months. Methods: Subjects received a remed eÒ System consisting of a respistimTM transvenous stimulation lead (in either the left pericardiophrenic or right brachiocephalic vein) and a remed eÒ pulse generator which was placed in the pectoral area and secured in a normal fashion. Thirty-five subjects with predominantly central sleep apnea were enrolled. Subjects had an ejection fraction < 40% Subjects (age 65AE9 years) and were able to be evaluated at 3 and 6 months of therapy. 62% percent of subjects had a concomitant cardiac device and 86% of subjects had chronic heart failure symptoms. Standard PSG criteria were used for classification of respiratory events and arousals. Results: Both 3 and 6 month data demonstrate significant improvements in apneahypopnea index (AHI), central apnea index, oxygen desaturation index of 4%, arousal index, REM sleep and sleep efficiency. In addition, there were significant improvements in quality of life at 6 months seen both in MLWHF (p¼0.0012) and NYHA Classification (p<0.0001).
TCT-134
Conclusions: Treatment of CSA with the remed eÒ System significantly improves both respiratory and sleep parameters as well as symptoms of heart failure, in patients with reduced EF. These favorable changes in pathophysiological consequences of sleep apnea may lead to improvements in outcomes in patients with heart failure. Background: To describe the technique and proof the concept of a complete transapical deployment of a single sidebranch arch endograft in a porcine model. Methods: Eight domestic pigs were operated with antegrade transapical delivery of a single-sidebranch arch endograft including a mating stentgraft to the innominate artery. Technical feasibility, operating time, radiation parameters and hemodynamic changes were studied according to standardized protocol during baseline (T0), after establishing of the transapical access and through-and-through wire (T1) and after stent-graft deployment (T2). Myocardial and cerebral perfusion were assessed by fluorescent-microspheres (FM) and transit-time-flow measurement (TTFM). Results: Transapical access, introduction and deployment of the endograft, sidebranch catheterization and deployment of the mating stent-graft were feasible in 6 of the 8 animals with unimpeded perfusion of the innominate artery. One animal was lost during transapical access, one during sire-branch catheterization. The mean operating and fluoroscopy times were 157AE47min and 15.9AE3.2min. During introduction and deployment of the stent-graft transient aortic valve insufficiency occurred in all animals. Hemodynamic stability recovered within ten minutes after retrieval of the delivery system in all animals. The innominate artery was patent with unchanged TTFM-flow measurements throughout the procedure. FM evaluation revealed stable myocardial and cerebral perfusion. Conclusions: Antegrade transapical access to the aortic arch for implantation of a single sidebranch arch endograft is feasible in a porcine model with reversible impact on hemodynamic measures during deployment. Transapical access allows for deployment of a complex endograft through a single large bore access-site in a porcine model. It might be a future treatment option for selective patients.
TCT-136
Results of a Novel Interatrial Shunt Therapy for Heart Failure and Preserved or Mildly Reduced Ejection Fraction Baker IDI Heart and Diabetes Institute, Melbourne, Australia Background: Diastolic dysfunction develops in most cardiac conditions, and leads to elevation of left ventricular filling pressures and heart failure. We report the initial experience with a novel device intended to lower left atrial pressure by creating a small permanent atrial septal shunt. The objective of the study was to evaluate safety and potential benefits of the Intra Atrial Shunt Device (IASDÔ) System in patients with symptomatic heart failure with preserved or mildly reduced ejection fraction, despite appropriate medical management. Methods: The first 6 patients in a prospective multicenter feasibility study were enrolled under an approved protocol. Key inclusion criteria were: EF > 45%; PCWP at rest ! 15 or exercise ! 25mm Hg; or ! 1 hospitalization for heart failure within prior 12 months; or persistent NYHA Class III/IV for at least 3 months. Results: Mean age, EF, and NYHA Class were 75 Y, 57 %, and III, respectively. Most patients had multiple comorbidities. The IASD Device was successfully implanted in each patient using standard interventional techniques and guidance. One SAE (complete heart block) occurred within 30 days, and resolved (pacemaker). The SAE was not related to the procedure or device. At 30 days, PCWP was reduced, and at 30 days clinical symptoms had improved in 5 of 6 patients. Additional follow-up data will be presented. O R A L S
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